Evidence map›Paper›PMID 33770118›Full record

ArticlePloS one2021

A two-hit model of alcoholic liver disease that exhibits rapid, severe fibrosis.

Monideepa Sengupta, Suomia Abuirqeba, Amina Kameric, Aurore Cecile-Valfort, Arindam Chatterjee, Kristine Griffett, Thomas P Burris, Colin A Flaveny

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Ethanol reshapes FFC-driven steatohepatitis through time-dependent fibrosis and lipid-droplet remodeling.American journal of physiology. Gastrointestinal and liver physiology · 2026
    Article
  3. Microplastics, nanoplastics and liver disease: an emerging health concern?Nature reviews. Gastroenterology & hepatology · 2026
    Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Pathogenesis of Alcohol-Associated Liver Disease.Journal of clinical and experimental hepatology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Monideepa SenguptaThe Department of Pharmacology and Physiology, Saint Louis University School of Medicine, Saint Louis, MO, United States of America.
Suomia AbuirqebaThe Department of Pharmacology and Physiology, Saint Louis University School of Medicine, Saint Louis, MO, United States of America.
Amina KamericThe Department of Pharmacology and Physiology, Saint Louis University School of Medicine, Saint Louis, MO, United States of America.
Aurore Cecile-ValfortCenter for Clinical Pharmacology at Washington University Saint Louis and The Saint Louis College of Pharmacy, Saint Louis, MO, United States of America.
Arindam ChatterjeeThe Department of Pharmacology and Physiology, Saint Louis University School of Medicine, Saint Louis, MO, United States of America.ORCID 0000-0002-2990-6389
Kristine GriffettCenter for Clinical Pharmacology at Washington University Saint Louis and The Saint Louis College of Pharmacy, Saint Louis, MO, United States of America.
Thomas P BurrisCenter for Clinical Pharmacology at Washington University Saint Louis and The Saint Louis College of Pharmacy, Saint Louis, MO, United States of America.
Colin A FlavenyThe Department of Pharmacology and Physiology, Saint Louis University School of Medicine, Saint Louis, MO, United States of America.ORCID 0000-0002-5391-715X
Saint Louis University · USUniversity of Health Sciences and Pharmacy · US

Funding

Treating prostate cancer by pharmacological coinhibition of the Warburg effect and lipogenesisR21CA205096 · NCI · SAINT LOUIS UNIVERSITY · PI FLAVENY, COLIN ASHTON · 2017 to 2018
$362k
Investigating Synthetic Ligands for the Treatment of NASHF32DK105845 · NIDDK · SAINT LOUIS UNIVERSITY · PI GRIFFETT, KRISTINE · 2015 to 2016
$116k
NCI NIH HHS R21 CA205096NIDDK NIH HHS F32 DK105845
6 · The paper itself

Abstract

Alcoholic liver disease (ALD) is responsible for an average of 50.4% and 44.2%of liver disease deaths among males and females respectively. Driven by alcohol misuse, ALD is often reversible by cessation of consumption. However, abstinence programs can have limited success at curtailing abuse, and the loss of life. ALD, therefore, remains a significant clinical challenge. There is a need for effective treatments that prevent or reverse alcohol-induced liver damage to complement or supplant behavioral interventions. Metabolic syndrome, which is disproportionally prevalent in ALD patients, accelerates the progression of ALD and increases liver disease mortality. Current rodent models of ALD unfortunately do not account for the contribution of the western diet to ALD pathology. To address this, we have developed a rodent model of ALD that integrates the impact of the western diet and alcohol; the WASH-diet model. We show here that the WASH diet, either chronically or in small time-restricted bouts, accelerated ALD pathology with severe steatohepatitis, elevated inflammation and increased fibrosis compared to mice receiving chronic alcohol alone. We also validated our WASH-diet model as an in vivo system for testing the efficacy of experimental ALD treatments. The efficacy of the inverse-agonist SR9238, previously shown to inhibit both non-alcohol and alcohol-induced steatohepatitis progression, was conserved in our WASH-diet model. These findings suggested that the WASH-diet may be useful for in vivo pre-clinical assessment of novel therapies.

Indexed as

Disease Models, AnimalLiver Diseases, AlcoholicAnimalsDiet, WesternEthanolFemaleLiverLiver CirrhosisMaleMiceMice, Inbred C57BLEthanol

Identifiers

PMID33770118
PMCPMC7996992
OpenAlexW3138075605

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.